News

Pharming Group N.V. announces it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).

Pharming Group reports strong financial results for the first half of 2019.

Pharming Webinar: halfjaarcijfers 2019 donderdag 25 juli 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!

Following receipt of the Dutch investigating centre’s ethics committee approval, Pharming announces it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia.

Pharming announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The presentation slides from today’s AGM are available on the Company’s website.

On 16 May each year, hereditary angioedema (HAE) patient organisations from around the world, led by the HAEi, the international umbrella organisation for the world’s HAE patient groups, come together to support awareness of HAE; a rare, potentially life-threatening condition. hae day :-) aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need to lead a better life.

Main results compared to Q1 2018: 19.5% increase in revenues, 49% increase in operating profit & 23% increase in net profit.

Pharming Group announces that the Notice to Convene for its Annual General Meeting of Shareholders has been uploaded on its website. Pharming’s upcoming Annual General Meeting will be held at the Holiday Inn (Haagse Schouwweg 10, 2332 KG Leiden, The Netherlands) on 22 May 2019 at 14:00 CEST.

Pharming announces that it has completed its investment of €1.6 million in cash and conversion of €2.5 million of prepayments into new equity in its Fill & Finish partner BioConnection BV.

Pharming Group announces the publication of its Annual Report for the financial year ended 31 December 2018, and a provisional commitment to invest in supplier BioConnection BV.